Pacira Pharmaceuticals (Nasdaq: PCRX) is expected to report Q4 earnings on March 7. Here's what Wall Street wants to see:

The 10-second takeaway
 Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Pacira Pharmaceuticals's revenues will grow 132.3% and EPS will remain in the red.

The average estimate for revenue is $9.8 million. On the bottom line, the average EPS estimate is -$0.42.

Revenue details
 Last quarter, Pacira Pharmaceuticals tallied revenue of $8.5 million. GAAP reported sales were much higher than the prior-year quarter's $4.0 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
 Last quarter, EPS came in at -$0.49. GAAP EPS were -$0.49 for Q3 compared to -$0.55 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
 For the preceding quarter, gross margin was -9.4%, much worse than the prior-year quarter. Operating margin was -185.1%, much better than the prior-year quarter. Net margin was -185.5%, much better than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $38.4 million. The average EPS estimate is -$1.63.

Investor sentiment
 The stock has a one-star rating (out of five) at Motley Fool CAPS, with 20 members out of 30 rating the stock outperform, and 10 members rating it underperform. Among 11 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), six give Pacira Pharmaceuticals a green thumbs-up, and five give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Pacira Pharmaceuticals is buy, with an average price target of $21.20.